NEW YORK - Immunocore e boletse hore Mantaha e tla rekisa likarolo tse 3,733,333 tumellanong ea lichelete tsa lichelete tsa poraefete (PIPE) e lebelletsoeng ho bokella $ 140 milione.
Tlas'a tumellano, Immunocore e tla rekisa thepa ea eona e tloaelehileng le ea ho se voute e tloaelehileng bakeng sa $ 37.50 ka kabelo. Batseteli ba teng ba k'hamphani ba kenyang letsoho licheleteng ba kenyelletsa RTW Investments, Rock Springs Capital le General Atlantic.Tumellano ea PIPE e lebelletsoe ho fela ka la 20 Phupu.
Khamphani e tla sebelisa chelete e fumanehang ho tšehetsa bakuli ba eona ba oncology le mafu a tšoaetsanoang, ho kenyelletsa le nts'etsopele ea mokhethoa oa eona oa pele oa oncology, Kimmtrak (tebentafusp-tebn), ho phekola HLA-A*02:01 letlalo le letle le uveal melanoma. Chelete, hammoho le chelete e tsoang ho Kimmtrak, e lebelletsoe ho tšehetsa ts'ebetso ea Immunocore2025.
Selemong sena, Kimmtrak e amohetsoe hore e sebelisoe ho bakuli ba nang le HLA-A * 02: 01 positive unresectable or metastatic uveal melanoma US, Europe le UK, har'a linaha tse ling.Immunocore e tsoela pele ho ithuta lithethefatsi thutong ea Phase I / II ho HLA-A * 02: 01-positive cutaneous melanoma.
Immunocore e boetse e nts'etsapele bakuli ba bang ba bane ba oncology, ho kenyelletsa le lithethefatsi tse ling tse peli tsa T-cell receptor litekong tsa Mokhahlelo oa I / II ka lihlahala tse tiileng tse tsoetseng pele. E 'ngoe ea lithethefatsi e ntse e ntlafatsoa bakeng sa bakuli ba HLA-A * 02:01-positive le MAGE-A4-positive, 'me sepheo se seng sa HLA-A * 02:01 le PRAME-positive e na le li-tumor tse peli tse sa tsejoeng
Leano la Lekunutu.melao le Lipehelo.Copyright © 2022 GenomeWeb, lekala la khoebo la Crain Communications.litokelo tsohle li sirelelitsoe.